12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GI-5005: Preliminary Phase IIb data

Preliminary data from an open-label Phase IIb trial in 27 patients with the T/T genotype of interleukin-28B (IL-28B; IFNL3) showed that GI-5005 plus pegylated interferon and ribavirin produced a 63% virologic response rate vs. 27% for pegylated interferon and ribavirin alone. GI-5005 "enhanced" HCV-specific...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >